Overview

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis (ALS)

Status:
RECRUITING
Trial end date:
2026-07-03
Target enrollment:
Participant gender:
Summary
Researchers will evaluate the safety, tolerability, and pharmacokinetics (PK) of orally administered Amisodin in healthy adult subjects through a randomized, double-blind, placebo-controlled Phase 1 study consisting of two parts: single ascending dose (SAD) and multiple ascending dose (MAD). The food effect will be assessed in one cohort in Part1. Approximately 32 healthy, adult subjects are planned to be enrolled in total. Subjects will participate in only one part and one cohort.
Phase:
PHASE1
Details
Lead Sponsor:
PRG Science & Technology Co., Ltd.